ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 057

A “High-Risk” Depression/Fatigue Profile May Be Associated with Stronger Response to a Psychological Treatment for Childhood-Onset Systemic Lupus Erythematosus (cSLE)

Elizabeth Ross1, khalid abulaban2, Elizabeth Kessler2, Andrea Knight3 and Natoshia Cunningham4, 1Michigan State University College of Human Medicine, Grand Rapids, MI, 2Helen DeVos Children's Hospital, Grand Rapids, MI, 3The Hospital for Sick Children, Toronto, ON, Canada, 4Michigan State University, Grand Rapids, MI

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: Anxiety, cognitive behavioral therapy, depression, Fatigue, juvenile SLE

  • Tweet
  • Email
  • Print
Session Information

Date: Thursday, March 30, 2023

Title: Posters: Clinical and Therapeutic I

Session Type: Poster Session A

Session Time: 6:00PM-7:00PM

Background/Purpose: Children with childhood-onset systemic lupus erythematosus (cSLE) experience more severe disease than their adult counterparts, in addition to high rates of clinical depressive symptoms (30%) and fatigue (65%) (1). A “high- risk” profile categorized by clinically elevated depressive symptoms and fatigue has been shown to be related to reduced health-related quality of life and poorer patient outcomes in cSLE patients (2). The Treatment and Education Approach for CHildhood-onset lupus (TEACH) is a tailored cognitive behavioral therapy (CBT) for youth with cSLE that may address these symptoms. (3). TEACH is currently being tested in an RCT with promising results after 6 weeks. However, it is unknown how the “high- risk” group may respond to this program. This study aims to assess the impact of risk status on the outcomes of cSLE patients undergoing CBT.

Methods: This study uses data from an ongoing multisite clinical trial of youth (average age of 17 years, 100% female, 70% identifying as from a minority group, n=46/60 currently completed evaluation for the study). All of these patients met the ACR criteria for cSLE. 16 of these youth have thus far been randomized to and completed TEACH. They were grouped into low- or high-risk categories based on baseline depression and fatigue t-scores ( >70; >2SD from mean) (3). Repeated measures ANOVAs were conducted to compare the low- and high-risk groups pre and post 6 week TEACH protocol for main study outcomes (e.g. depressive symptoms (CDI-II), fatigue (PROMIS), and pain (VAS)) and additional exploratory outcomes (anxiety (SCARED), disease severity (SLEDAI), and health-related quality of life (Peds-QL)). Independent samples t-test was used to determine if baseline outcome measures were significantly different between low- and high-risk groups.

Results: Out of the 16 patients who have completed the TEACH protocol, 6 (37.5%) met criteria for inclusion in the high-risk group. There was no significant difference between risk groups based on age, disease duration, or self-reported race. There was a significant difference between groups in baseline depression scores only (p= 0.005). At week 6 after completion of TEACH, depression scores decreased by 26% in the high- risk group, while the low- risk group only decreased 6% (p < 0.001; Table 1). Fatigue, anxiety, health-related quality of life, and disease severity followed the same trends (see Figure 1). Despite these trends, there were no significant differences found between the low- and high-risk groups in any outcomes other than depressive symptoms.

Conclusion: There is very little literature on nonpharmacologic treatments for cSLE like CBT (4). These data reveal interesting trends that CBT may be more effective in cSLE patients with high levels of fatigue and depression. Some results may be driven by the fact that the high-risk group begins with higher baseline symptoms. Lack of significant difference between groups may be attributed to a small sample size and these analyses should be replicated with a larger data set (e.g., upon completion of the RCT) in the future. Although the high-risk group shows more improvement overall, this should not shadow that both high- and low- risk groups had improved outcomes with the TEACH protocol.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: E. Ross: None; k. abulaban: None; E. Kessler: None; A. Knight: None; N. Cunningham: None.

To cite this abstract in AMA style:

Ross E, abulaban k, Kessler E, Knight A, Cunningham N. A “High-Risk” Depression/Fatigue Profile May Be Associated with Stronger Response to a Psychological Treatment for Childhood-Onset Systemic Lupus Erythematosus (cSLE) [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/a-high-risk-depression-fatigue-profile-may-be-associated-with-stronger-response-to-a-psychological-treatment-for-childhood-onset-systemic-lupus-erythematosus-csle/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-high-risk-depression-fatigue-profile-may-be-associated-with-stronger-response-to-a-psychological-treatment-for-childhood-onset-systemic-lupus-erythematosus-csle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology